Pipeline

Innovation is in GenSci's DNA. GenSci advances a robust, innovative portfolio across four therapeutic areas: endocrinology & metabolism, women's health, immunology & respiratory diseases, and oncology.

The pipeline is updated quarterly. Last updated December 2025.
The pipeline is approved in at least one major market, such as China, USA and/or EU.
Only selected pipeline molecules are presented here.

Endocrinology / Metabolic Pipeline

Molecule

Indication(s)

Target(s)

IND

Phase Ⅰ

Phase Ⅱ

Phase Ⅲ

Registration

Launch

Givopegsomatropin Solution Injection

GHD，ISS，TS

GHR

GenSci134

AGHD, PGHD, ISS

GHR

GenSci098

GD

TSHR

Endocrinology / Metabolic Pipeline

- IND
- Phase Ⅰ
- Phase Ⅱ
- Phase Ⅲ
- Registration
- Launch
- Givopegsomatropin Solution Injection
  
  GHD，ISS，TS
  
  GHR
- GenSci134
  
  AGHD, PGHD, ISS
  
  GHR
- GenSci098
  
  GD
  
  TSHR